Trial
NCT04999020
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Dermatomyositis
Intervention
Ravulizumab
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-09